Following the publication of his article last year: How short-term gain can lead to long-term pain, we caught up with David James, CEO of Scinogy, to discuss whether the conversation has started to change within the industry as the sector looks to drive down costs and automate manufacturing of cell and gene therapies.  

For the commercial success of advanced therapies including CAR-T, they must not only be safe and effective, but also consistently produced and delivered to patients at a cost they can afford.  What many advanced therapy companies either fail to realize or choose to ignore is that the decisions made during early development have a profound and long-lasting impact on the success of the therapy. This article provides valuable insight into some of the factors critical to successful commercialization of an advanced therapy to help prevent short-term gains from becoming long-term pain

Advanced therapy manufacturing and automation experts, Scinogy, join the CRC for Cell Therapy Manufacturing (CTM CRC) to accelerate development of next gen cell therapy manufacturing.

The addition of Scinogy’s experience in manufacturing systems for cell therapy, complements CTM CRC’s expertise in surface functionalisation and new materials technologies. This powerful combination of capabilities will better address current manufacturing challenges, such as scalability and cost.